Japan Digestive Disease Week 2022
International Poster Session6 (JDDW)
October 28, 14:00–14:40, Room 15 (Marine Messe Fukuoka Arena Digital Poster Session)
IP-27_G
Combination treatment with polaprezinc and sodium selenite attenuates hepatic fibrosis and steatosis in an experimental animal model of NASH
- 1
- Department of Medical Technology, Kagawa Prefectural University of Health Sciences
- 2
- Department of Surgery, Engaru-Kosei General Hospital
【Aim】We investigated the efficacy of the combination treatment with polaprezinc and sodium selenite in a model of nonalcoholic steatohepatitis (NASH).
【Methods】C57BL/6J male mice were injected with streptozotocin 2days after birth, and subsequently fed a high fat diet (HFD). 5-week-old mice were divided into 4 groups: control group (HFD only), Zn group (HFD + polaprezinc 45mg/Kg), Se group (HFD + sodium selenite 150μg/Kg) and Zn + Se group (HFD + polaprezinc 45mg/Kg + sodium selenite 150μg/Kg). Biochemical and histological findings were evaluated in each group at 9-week-old.
【Results】Serum ALT and ferritin levels were significantly decreased in the Zn + Se group, compared to those in other groups. This combination therapy markedly inhibited hepatic steatosis, lobular inflammation and hepatocyte ballooning through downregulation of tumor necrosis factor-a and malondialdehyde. Recruitment of macrophage in the liver was significantly suppressed in the Zn + Se group. The severity of hepatic fibrosis was also markedly improved by the combination therapy.
【Conclusion】The combination treatment with polaprezinc and sodium selenite may be a promising therapeutic strategy for NASH.
【Methods】C57BL/6J male mice were injected with streptozotocin 2days after birth, and subsequently fed a high fat diet (HFD). 5-week-old mice were divided into 4 groups: control group (HFD only), Zn group (HFD + polaprezinc 45mg/Kg), Se group (HFD + sodium selenite 150μg/Kg) and Zn + Se group (HFD + polaprezinc 45mg/Kg + sodium selenite 150μg/Kg). Biochemical and histological findings were evaluated in each group at 9-week-old.
【Results】Serum ALT and ferritin levels were significantly decreased in the Zn + Se group, compared to those in other groups. This combination therapy markedly inhibited hepatic steatosis, lobular inflammation and hepatocyte ballooning through downregulation of tumor necrosis factor-a and malondialdehyde. Recruitment of macrophage in the liver was significantly suppressed in the Zn + Se group. The severity of hepatic fibrosis was also markedly improved by the combination therapy.
【Conclusion】The combination treatment with polaprezinc and sodium selenite may be a promising therapeutic strategy for NASH.
- Index Term 1: zinc
- Index Term 2: NASH